• Paul A Lapchak.
• University of California San Diego, Department of Neurosciences, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA. plapchak@ucsd.edu
• Expert Opin Investig Drugs. 2008 Aug 1;17(8):1175-86.

BackgroundCarbamylated erythropoietin (CEPO) is a modified erythropoietin molecule not affecting hematocrit. It is a potentially important pharmacological agent that may be applied to the treatment of several diseases affecting central and peripheral system neurons.ObjectiveCarbamylated erythropoietin is a prime candidate for development because of its potent cell survival and function enhancing effects. This article reviews the preclinical development profile of CEPO in animal models to determine whether further clinical development is justified.MethodsThe review spans a detailed analysis of patents and scientific publications related to CEPO in animal models.Results/ConclusionsUse of CEPO in treating diseases such as stroke and traumatic brain and spinal cord injuries is important because these conditions affect millions of patients every year. Extensive preclinical studies support further clinical studies of CEPO for acute ischemic stroke. However, further studies are required for testing CEPO in patients with many other indications.

22 keywords...

hide…